KOD · Kodiak Sciences Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $48.55M | - | $50.48M | $42.76M | $43.64M | - | $31.88M | $32.51M | $29.93M | - |
| SG&A | $11.23M | - | $11.88M | $12.75M | $15.43M | - | $14.75M | $15.47M | $16.12M | - |
| Total Operating Expenses | $59.78M | - | $62.35M | $55.51M | $59.07M | - | $46.63M | $47.98M | $46.05M | - |
| D&A | $4.11M | - | - | - | $4.60M | - | - | - | $4.70M | - |
| Operating Income | ($59.78M) | - | ($62.35M) | ($55.51M) | ($59.07M) | - | ($46.63M) | ($47.98M) | ($46.05M) | - |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($58.16M) | - | ($61.46M) | ($54.31M) | ($57.46M) | - | ($43.95M) | ($45.12M) | ($43.04M) | - |
| EPS - Basic | ($0.94) | - | ($1.16) | ($1.03) | ($1.09) | - | ($0.84) | ($0.86) | ($0.82) | - |
| EPS - Diluted | ($0.94) | - | ($1.16) | ($1.03) | ($1.09) | - | ($0.84) | ($0.86) | ($0.82) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $169.53M | $209.86M | $72.04M | $104.17M | $138.85M | $168.07M | $197.86M | $219.22M | $245.92M | $285.51M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $11.34M | $12.86M | $10.37M | $5.06M | $6.54M | $3.92M | $3.29M | $1.87M | $2.48M | $13.61M |
| Current Assets | $175.26M | $214.82M | $75.73M | $107.92M | $142.69M | $171.94M | $202.49M | $224.63M | $251.51M | $289.31M |
| Total Assets | $306.01M | $351.53M | $218.07M | $256.73M | $297.91M | $335.58M | $372.67M | $401.58M | $434.76M | $479.37M |
| Current Liabilities | $49.57M | $45.53M | $42.43M | $31.01M | $30.88M | $25.57M | $24.06M | $21.20M | $24.86M | $41.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $193.91M | $194.15M | $194.38M | $186.44M | $189.07M | $185.29M | $187.30M | $187.07M | $193.57M | $213.59M |
| Stockholders' Equity | $112.10M | $157.38M | $23.69M | $70.29M | $108.84M | $150.29M | $185.37M | $214.51M | $241.19M | $265.78M |
| Retained Earnings | ($1.62B) | ($1.56B) | ($1.50B) | ($1.44B) | ($1.39B) | ($1.33B) | ($1.28B) | ($1.24B) | ($1.20B) | ($1.15B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($40.01M) | - | - | - | ($29.08M) | - | - | - | ($39.60M) | - |
| Investing Cash Flow | ($942.0K) | - | - | - | ($270.0K) | - | - | - | ($166.0K) | - |
| Financing Cash Flow | $619.0K | - | - | - | $124.0K | - | - | - | $38.0K | - |
| CapEx | $942.0K | - | - | - | $270.0K | - | - | - | $22.0K | - |
| Free Cash Flow | ($40.95M) | - | - | - | ($29.35M) | - | - | - | ($39.62M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.70 | - | - | - | 0.51 | - | - | - | 0.92 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.0% | - | -28.2% | -21.2% | -19.3% | - | -11.8% | -11.2% | -9.9% | - |
| Return on equity | -51.9% | - | -259.4% | -77.3% | -52.8% | - | -23.7% | -21.0% | -17.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.54 | 4.72 | 1.78 | 3.48 | 4.62 | 6.72 | 8.42 | 10.59 | 10.12 | 6.93 |
| Quick ratio | 3.54 | 4.72 | 1.78 | 3.48 | 4.62 | 6.72 | 8.42 | 10.59 | 10.12 | 6.93 |
| Cash ratio | 3.42 | 4.61 | 1.70 | 3.36 | 4.50 | 6.57 | 8.22 | 10.34 | 9.89 | 6.84 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.73 | 2.23 | 9.20 | 3.65 | 2.74 | 2.23 | 2.01 | 1.87 | 1.80 | 1.80 |
| Liabilities / Assets | 0.63 | 0.55 | 0.89 | 0.73 | 0.63 | 0.55 | 0.50 | 0.47 | 0.45 | 0.45 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 21.0x | - | 36.5x | 2.8x | 1.4x | - | 0.7x | 0.6x | 1.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1.2% | - | -33.7% | -15.7% | -28.3% | - | 14.4% | 43.4% | 38.3% | - |
| Net income growth (YoY) | -1.2% | - | -39.8% | -20.4% | -33.5% | - | 12.1% | 43.7% | 39.2% | - |
| EPS growth (YoY) | 13.8% | - | -38.1% | -19.8% | -32.9% | - | 11.6% | 43.8% | 39.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -39.5% | - | - | - | 25.9% | - | - | - | 33.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 3.0% | 4.7% | -87.2% | -67.2% | -54.9% | -43.5% | -38.7% | -36.6% | -38.6% | -39.1% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Kodiak Sciences Inc. against the 5 most active filers in the same SIC group.